Eton Pharmaceuticals (ETON) Stock Forecast, Price Target & Predictions
ETON Stock Forecast
Eton Pharmaceuticals stock forecast is as follows: an average price target of $13.00 (represents a 20.93% upside from ETON’s last price of $10.75) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
ETON Price Target
The average price target for Eton Pharmaceuticals (ETON) is $13.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $11.00. This represents a potential 20.93% upside from ETON's last price of $10.75.
ETON Analyst Ratings
According to 6 Wall Street analysts, Eton Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ETON stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Eton Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 28, 2024 | Chase Knickerbocker | Craig-Hallum | - | - | 77.73% | 39.53% |
| Oct 04, 2024 | Swayampakula Ramakanth | H.C. Wainwright | - | - | 59.19% | 2.33% |
| May 06, 2024 | Chase Knickerbocker | Craig-Hallum | - | - | 115.63% | -25.58% |
| Jul 25, 2022 | H.C. Wainwright | - | - | 230.88% | -16.28% |
The latest Eton Pharmaceuticals stock forecast, released on Oct 28, 2024 by Chase Knickerbocker from Craig-Hallum, set a price target of $15.00, which represents a 77.73% increase from the stock price at the time of the forecast ($8.44), and a 39.53% increase from ETON last price ($10.75).
Eton Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 3 |
| Avg Price Target | $15.00 | $13.00 | $11.33 |
| Last Closing Price | $10.75 | $10.75 | $10.75 |
| Upside/Downside | 39.53% | 20.93% | 5.40% |
In the current month, the average price target of Eton Pharmaceuticals stock is $15.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 39.53% increase as opposed to Eton Pharmaceuticals's last price of $10.75. This month's average price target is up 15.38% compared to last quarter, and up 32.39% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 28, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Oct 04, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Oct 04, 2024 | Deutsche Bank | Buy | Buy | Hold |
| Oct 04, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Oct 04, 2024 | Macquarie | Buy | Buy | Hold |
| Oct 04, 2024 | Cowen & Co. | Buy | Upgrade | |
| Oct 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 06, 2024 | Craig-Hallum | Buy | Initialise |
Eton Pharmaceuticals's last stock rating was published by Craig-Hallum on Oct 28, 2024. The company gave ETON a "Buy" rating, the same as its previous rate.
Eton Pharmaceuticals Financial Forecast
Eton Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $7.03M | $12.00M | $5.30M | $8.50M | $3.22M | $7.36M | $2.18M | $6.09M | $775.00K | $3.07M | $11.90M | $81.00K | $-161.00K | $20.00K | $99.00K | $459.00K | - |
| Avg Forecast | $20.35M | $18.40M | $15.60M | $14.80M | $10.80M | $9.70M | $8.80M | $7.70M | $7.70M | $6.26M | $6.50M | $4.60M | $9.10M | $3.05M | $7.80M | $7.10M | $7.56M | $3.04M | $3.83M | $12.05M | $1.04M | $1.06M | $294.33K | $1.51M | $670.33K | $777.78K |
| High Forecast | $21.26M | $19.22M | $16.30M | $15.46M | $11.28M | $9.79M | $9.19M | $8.04M | $8.04M | $6.54M | $6.79M | $4.81M | $9.51M | $3.05M | $7.80M | $7.10M | $7.56M | $3.04M | $3.83M | $12.05M | $1.04M | $1.06M | $294.33K | $1.51M | $670.33K | $933.33K |
| Low Forecast | $19.44M | $17.58M | $14.90M | $14.14M | $10.32M | $9.60M | $8.41M | $7.36M | $7.36M | $5.98M | $6.21M | $4.39M | $8.69M | $3.05M | $7.80M | $7.10M | $7.56M | $3.04M | $3.83M | $12.05M | $1.04M | $1.06M | $294.33K | $1.51M | $670.33K | $622.22K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.12% | 1.85% | 1.15% | 0.93% | 1.06% | 0.94% | 0.31% | 0.81% | 0.25% | 0.80% | 0.99% | 0.08% | -0.15% | 0.07% | 0.07% | 0.68% | - |
Eton Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 1 analysts is $7.70M, with a low forecast of $7.36M, and a high forecast of $8.04M. ETON's average Quarter revenue forecast represents a 9.56% increase compared to the company's last Quarter revenue of $7.03M (Sep 23).
Eton Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-548.00K | $3.88M | $-2.32M | $1.06M | $-2.73M | $-169.00K | $-4.91M | $1.45M | $-6.01M | $-1.93M | $5.52M | $-7.53M | $-6.34M | $-4.57M | $-8.89M | $-2.55M | $-3.13M |
| Avg Forecast | $-9.63M | $-8.71M | $-7.38M | $-7.00M | $-5.11M | $-4.59M | $-4.16M | $-3.64M | $-3.64M | $-2.96M | $-3.08M | $-2.18M | $-4.31M | $-1.44M | $-3.68M | $-3.07M | $-3.57M | $-1.44M | $-1.81M | $5.52M | $-492.18K | $-500.37K | $-139.03K | $-4.61M | $-316.63K | $-4.38M |
| High Forecast | $-9.20M | $-8.32M | $-7.05M | $-6.69M | $-4.88M | $-4.54M | $-3.98M | $-3.48M | $-3.48M | $-2.83M | $-2.94M | $-2.08M | $-4.11M | $-1.44M | $-3.68M | $-2.45M | $-3.57M | $-1.44M | $-1.81M | $6.62M | $-492.18K | $-500.37K | $-139.03K | $-3.69M | $-316.63K | $-3.50M |
| Low Forecast | $-10.06M | $-9.09M | $-7.71M | $-7.32M | $-5.34M | $-4.63M | $-4.35M | $-3.81M | $-3.81M | $-3.09M | $-3.21M | $-2.27M | $-4.50M | $-1.44M | $-3.68M | $-3.68M | $-3.57M | $-1.44M | $-1.81M | $4.41M | $-492.18K | $-500.37K | $-139.03K | $-5.53M | $-316.63K | $-5.25M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.19% | -1.26% | 1.07% | -0.25% | 1.89% | 0.05% | 1.60% | -0.41% | 4.18% | 1.07% | 1.00% | 15.29% | 12.67% | 32.84% | 1.93% | 8.05% | 0.71% |
1 analysts predict ETON's average Quarter EBITDA for Sep 23 to be $-2.96M, with a high of $-2.83M and a low of $-3.09M. This is -176.27% lower than Eton Pharmaceuticals's previous annual EBITDA (Jun 23) of $3.88M.
Eton Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | $-579.00K | $4.56M | $-2.91M | $912.00K | $-3.19M | $-1.78M | $-5.57M | $764.00K | $-6.09M | $-2.02M | $5.12M | $-7.69M | $-6.50M | $-4.73M | $-9.05M | $-2.70M | $-3.25M |
| Avg Forecast | $4.78M | $3.72M | $1.86M | $1.73M | $-398.25K | $-265.50K | $-1.86M | $-1.86M | $-1.06M | $-2.65M | $-2.39M | $-3.72M | $265.50K | $-3.87M | $773.34K | $-3.33M | $1.29M | $-3.48M | $-3.61M | $5.12M | $-6.83M | $-6.53M | $-6.70M | $-4.69M | $-6.79M | $-4.41M |
| High Forecast | $5.06M | $3.93M | $1.97M | $1.83M | $-375.15K | $-250.10K | $-1.75M | $-1.75M | $-1.00M | $-2.50M | $-2.25M | $-3.50M | $280.90K | $-3.87M | $773.34K | $-2.67M | $1.29M | $-3.48M | $-3.61M | $6.14M | $-6.83M | $-6.53M | $-6.70M | $-3.75M | $-6.79M | $-3.53M |
| Low Forecast | $4.50M | $3.50M | $1.75M | $1.63M | $-421.35K | $-280.90K | $-1.97M | $-1.97M | $-1.12M | $-2.81M | $-2.53M | $-3.93M | $250.10K | $-3.87M | $773.34K | $-4.00M | $1.29M | $-3.48M | $-3.61M | $4.09M | $-6.83M | $-6.53M | $-6.70M | $-5.63M | $-6.79M | $-5.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.22% | -1.91% | 0.78% | 3.44% | 0.83% | -2.30% | 1.67% | 0.59% | 1.75% | 0.56% | 1.00% | 1.13% | 1.00% | 0.71% | 1.93% | 0.40% | 0.74% |
Eton Pharmaceuticals's average Quarter net income forecast for Sep 23 is $-2.65M, with a range of $-2.81M to $-2.50M. ETON's average Quarter net income forecast represents a -158.24% decrease compared to the company's last Quarter net income of $4.56M (Jun 23).
Eton Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | $4.34M | $4.67M | $5.34M | $4.35M | $4.17M | $5.26M | $4.93M | $3.82M | $3.33M | $3.27M | $4.06M | $3.80M | $3.43M | $2.92M | $2.61M | $2.43M | $1.91M |
| Avg Forecast | $1.37B | $1.24B | $1.05B | $998.08M | $728.33M | $653.84M | $593.45M | $519.27M | $519.27M | $422.09M | $438.35M | $310.21M | $613.69M | $205.62M | $526.02M | $3.08M | $510.03M | $205.08M | $258.42M | $4.06M | $70.27M | $71.44M | $19.85M | $1.35M | $45.21M | $52.45M |
| High Forecast | $1.43B | $1.30B | $1.10B | $1.04B | $760.83M | $660.44M | $619.94M | $542.44M | $542.44M | $440.93M | $457.91M | $324.06M | $641.07M | $205.62M | $526.02M | $3.70M | $510.03M | $205.08M | $258.42M | $4.87M | $70.27M | $71.44M | $19.85M | $1.62M | $45.21M | $62.94M |
| Low Forecast | $1.31B | $1.19B | $1.01B | $953.54M | $695.83M | $647.25M | $566.97M | $496.10M | $496.10M | $403.26M | $418.79M | $296.37M | $586.30M | $205.62M | $526.02M | $2.46M | $510.03M | $205.08M | $258.42M | $3.25M | $70.27M | $71.44M | $19.85M | $1.08M | $45.21M | $41.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.01% | 0.01% | 0.02% | 0.01% | 0.02% | 0.01% | 1.60% | 0.01% | 0.02% | 0.01% | 1.00% | 0.05% | 0.05% | 0.15% | 1.93% | 0.05% | 0.04% |
Eton Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $519.27M, based on 1 Wall Street analysts, with a range of $496.10M to $542.44M. The forecast indicates a 11875.84% rise compared to ETON last annual SG&A of $4.34M (Sep 23).
Eton Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.02 | $0.18 | $-0.11 | $0.04 | $-0.13 | $-0.07 | $-0.22 | $0.03 | $-0.24 | $-0.08 | $0.21 | $-0.32 | $-0.31 | $-0.23 | $-0.50 | $-0.15 | $-0.18 |
| Avg Forecast | $0.18 | $0.14 | $0.07 | $0.07 | $-0.01 | $-0.01 | $-0.07 | $-0.07 | $-0.04 | $-0.10 | $-0.09 | $-0.14 | $0.01 | $-0.15 | $0.03 | $-0.08 | $0.05 | $-0.14 | $-0.14 | $0.19 | $-0.27 | $-0.25 | $-0.26 | $-0.22 | $-0.26 | $-0.28 |
| High Forecast | $0.19 | $0.15 | $0.07 | $0.07 | $-0.01 | $-0.01 | $-0.07 | $-0.07 | $-0.04 | $-0.09 | $-0.08 | $-0.13 | $0.01 | $-0.15 | $0.03 | $-0.08 | $0.05 | $-0.14 | $-0.14 | $0.19 | $-0.27 | $-0.25 | $-0.26 | $-0.22 | $-0.26 | $-0.28 |
| Low Forecast | $0.17 | $0.13 | $0.07 | $0.06 | $-0.02 | $-0.01 | $-0.07 | $-0.07 | $-0.04 | $-0.11 | $-0.10 | $-0.15 | $0.01 | $-0.15 | $0.03 | $-0.08 | $0.05 | $-0.14 | $-0.14 | $0.19 | $-0.27 | $-0.25 | $-0.26 | $-0.22 | $-0.26 | $-0.28 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.22% | -2.00% | 0.79% | 4.00% | 0.87% | -2.36% | 2.75% | 0.60% | 1.78% | 0.57% | 1.11% | 1.21% | 1.22% | 0.88% | 2.24% | 0.57% | 0.65% |
According to 1 Wall Street analysts, Eton Pharmaceuticals's projected average Quarter EPS for Sep 23 is $-0.10, with a low estimate of $-0.11 and a high estimate of $-0.09. This represents a -155.56% decrease compared to ETON previous annual EPS of $0.18 (Jun 23).
Eton Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PASG | Passage Bio | - | - | 1011.11% | Buy |
| BDTX | Black Diamond Therapeutics | - | - | 507.00% | Buy |
| GOSS | Gossamer Bio | - | - | 468.18% | Buy |
| ABOS | Acumen Pharmaceuticals | - | - | 203.03% | Buy |
| LYRA | Lyra Therapeutics | - | - | 177.78% | Hold |
| ELYM | Eliem Therapeutics | - | - | 154.40% | Buy |
| NUVB | Nuvation Bio | - | - | 150.00% | Buy |
| CELC | Celcuity | - | - | 147.45% | Buy |
| ALDX | Aldeyra Therapeutics | - | - | 128.69% | Buy |
| REPL | Replimune Group | - | - | 119.00% | Buy |
| KRON | Kronos Bio | - | - | 87.36% | Buy |
| ELVN | Enliven Therapeutics | - | - | 55.45% | Buy |
| CNTB | Connect Biopharma | - | - | 51.52% | Buy |
| TARS | Tarsus Pharmaceuticals | - | - | 33.62% | Buy |
| ETON | Eton Pharmaceuticals | - | - | 20.93% | Buy |
| TVTX | Travere Therapeutics | - | - | 19.11% | Buy |
| ALEC | Alector | - | - | 6.38% | Buy |